🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise around the world, with estimates suggesting over 82 million infections annually. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the face of growing infection rates, escalating drug resistance and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Data and Global Access

Based on data published in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which combines a dual-drug approach. The trial enrolled nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of developing nations.

Clinicians directly involved have voiced hope. Having a easy-to-administer therapy such as this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed vital to lessen the impact of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.